{
    "2019-06-13": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris",
                "features": {
                    "keywords": [
                        "Roche",
                        "Rituxan",
                        "Positive Data",
                        "Pemphigus Vulgaris"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Top Analyst Reports for Visa, Netflix & Accenture",
                "features": {
                    "keywords": [
                        "Analyst Reports",
                        "Visa",
                        "Netflix",
                        "Accenture"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "financial services",
                        "consulting"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Ligand Inks Oncology Drug Discovery Deal With PhoreMost",
                "features": {
                    "keywords": [
                        "Ligand",
                        "Oncology",
                        "Drug Discovery",
                        "PhoreMost"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "A Stock Fund Challenges the Definition of Growth. Itâ€™s Paying Off.",
                "features": {
                    "keywords": [
                        "Stock Fund",
                        "Growth Definition",
                        "Paying Off"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "investing"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "Novartis Reports Data on Cosentyx for Psoriatic Arthritis",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Cosentyx",
                        "Psoriatic Arthritis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-08-25",
                "original_text": "Roche's Rituxan Gets Priority Review for Blood Disorder",
                "features": {
                    "keywords": [
                        "Roche",
                        "Rituxan",
                        "Priority Review",
                        "Blood Disorder"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}